InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Insider track record
CEODisclosed buys
0
Disclosed sells
0
T+90 hit rate
47%
T+90 mean return
-6.4%
Across 15 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the full record of transactions filed by Mills Kenneth T., Chairman & CEO. Insider active across 1 company, notably REGENXBIO Inc.. Aggregated, 25 filings have been recorded. History available since 24 June 2021. The latest transaction was filed on 12 May 2025 (Levée d'options). Regulator: SEC (Form 4). The full history is openly available.
Declarations25 total
20,602 shares@ US$3.764.9% of flowCommon StockSEC:0001562180-25-003822:0
30,752 shares@ US$3.767.6% of flowCommon StockSEC:0001562180-25-002804:0
36,316 shares@ US$0.852.0% of flowCommon StockSEC:0001562180-24-006146:0
12,221 shares@ US$3.763.0% of flowCommon StockSEC:0001562180-24-005855:0
200 shares@ US$3.760.0% of flowCommon StockSEC:0001562180-24-005798:0
15,000 shares@ US$3.763.7% of flowCommon StockSEC:0001562180-24-004104:0
15,000 shares@ US$3.763.7% of flowCommon StockSEC:0001562180-24-003452:0
15,000 shares@ US$3.763.6% of flowCommon StockSEC:0001562180-24-002771:0
15,000 shares@ US$3.763.7% of flowCommon StockSEC:0001562180-24-001395:0
45,000 shares@ US$3.7610.9% of flowCommon StockSEC:0001562180-24-000544:0
11,357 shares@ US$17.9513.0% of flowCommon StockSEC:0001562180-24-000223:0
43,500 shares@ US$3.7610.5% of flowCommon StockSEC:0001562180-23-008519:0
9,308 shares@ US$22.6813.9% of flowCommon StockSEC:0001562180-23-000221:0
3,636 shares@ US$32.707.4% of flowCommon StockSEC:0001562180-22-000149
3,636 shares@ US$32.700.036% mcap37.9% of flowCommon StockSEC:0001562180-22-000149:0
3,300 shares0Common StockSEC:0001562180-21-007473:0
3,300 shares0Common StockSEC:0001562180-21-007473
1,500 shares@ US$3.760.0016% mcap1.8% of flowCommon StockSEC:0001562180-21-006967:0
1,500 shares@ US$3.760.3% of flowCommon StockSEC:0001562180-21-006967
1,500 shares@ US$3.760.3% of flowCommon StockSEC:0001562180-21-006147
1,500 shares@ US$3.760.0016% mcap1.7% of flowCommon StockSEC:0001562180-21-006147:0
3,000 shares@ US$3.760.0032% mcap3.4% of flowCommon StockSEC:0001562180-21-005947:0
3,000 shares@ US$3.760.7% of flowCommon StockSEC:0001562180-21-005947
4,500 shares@ US$3.761.0% of flowCommon StockSEC:0001562180-21-004525
4,500 shares@ US$3.760.0048% mcap5.1% of flowCommon StockSEC:0001562180-21-004525:0
25 of 25 declarations
About Mills Kenneth T.
Kenneth T. Mills is the President and CEO of REGENXBIO Inc. He leads the company in its mission to develop innovative gene therapies for the treatment of serious genetic diseases. Under his leadership, REGENXBIO has focused on advancing its research and development programs aimed at improving patient lives. Kenneth T. Mills has extensive experience in the biopharmaceutical sector, enabling him to effectively guide the company in a constantly evolving environment.
